← Leaderboards
Nathanael McCurley
Haplomics, Inc.
$2,633,499
Attributed
$2,633,499
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2015–24$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,633,499 · 2
By mechanism
R42$2,399,999 · 1
R43$233,500 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoAntibodiesProductionMediatingClinical TrialsDoseImmunogenicPre-ClinicalProgramsChronicAntigen PresentationAdaptive Immune ResponseAntigensCd47 GeneCancer VaccinationColorectalCancer PatientBusinessesCancer CellClinical TranslationAcuteCancer ImmunotherapyAnti-CancerBiodistribution
Grant awards (4)
SIRPant Technology for anti-Cancer Immunity$999,999
R42 · FY2024 · CA · contact PI
SIRPant Technology for anti-Cancer Immunity$1,000,000
R42 · FY2023 · CA · contact PI
SIRPant Technology for anti-Cancer Immunity$400,000
R42 · FY2021 · CA · contact PI
Strategies for Personalized Gene Repair using I22I Severe Hemophilia-A as a Model$233,500
R43 · FY2015 · MD · contact PI